Buying the Dip on Palantir Stock? Read This First

Palantir’s revenue rose 70% year over year to $1.41 billion last quarter, with U.S. commercial revenue up 137%, but the article argues the stock remains too expensive at a 68x trailing price-to-sales ratio. It also flags 28% share-count growth over five years as a dilution headwind that could add roughly $100 billion to market cap over the next five years if unchanged. The piece recommends waiting for further dips rather than buying now.

Analysis

PLTR’s fundamental momentum is real, but the market is implicitly underwriting a far larger and broader end-state than the current business mix can justify. When a company trades at a premium this extreme, the hidden risk is not just multiple compression; it is that every incremental beat gets capitalized into a valuation framework with almost no room for execution slippage. That makes the stock far more sensitive to any evidence that growth is decelerating even modestly, especially over the next 1-2 quarters when sentiment can flip faster than the business.

The larger second-order issue is compensation-induced supply. In a name where demand is already crowded and narrative-driven, persistent dilution acts like a structural overhang on per-share fundamentals even if headline revenue and margin continue to improve. That matters most over a 12-36 month horizon: investors may be underwriting compound growth, but per-share value creation can lag badly if issuance remains elevated, forcing the market to pay up for growth that is only partially accruing to common holders.

The contrarian view is that consensus may be underestimating how long “scarcity premium” stocks can stay expensive when AI enthusiasm remains the dominant macro factor. If the company keeps printing outsized U.S. commercial growth and converts that into visible backlog expansion, the stock can remain disconnected from traditional valuation anchors for longer than bears expect. But that setup is asymmetric: upside likely comes from multiple persistence, while downside is accelerated by any deceleration in growth, dilution commentary, or a broader AI de-rating.

Relative to peers, the cleaner expression is not a naked short unless you have a catalyst window; a pair against a higher-quality, more diversified software compounder makes more sense. The market is effectively pricing PLTR as a platform monopoly without giving enough credit to customer concentration, product concentration, and issuance drag, so the more likely path is grinding underperformance rather than an immediate collapse. The key is timing: this is a better short on a post-earnings pop or any broad AI squeeze than into a weak tape where short interest can get squeezed hard.

Key Decisions for Investors

• Avoid initiating a fresh long in PLTR at current levels; if forced to own, wait for a 15-20% drawdown or a post-earnings gap-down to improve the forward risk/reward over a 6-12 month horizon.
• Use a pair trade: short PLTR / long ADBE or CRM on a 3-6 month view, targeting valuation normalization while limiting exposure to AI/software factor beta; best entry is after PLTR strength, not weakness.
• For higher-conviction bearish exposure, buy PLTR puts 3-6 months out on any rally back toward prior highs; the best payoff comes from multiple compression rather than absolute business deterioration.
• If already long PLTR, trim into strength and hedge with short-dated calls against the position into earnings; this monetizes volatility while protecting against a 1-2 quarter sentiment reversal.
• Watch dilution disclosures and SBC trajectory closely; if share count growth remains near recent pace for another two quarters, the thesis shifts from 'expensive growth' to 'value leakage,' increasing the probability of sustained underperformance.